Patented Out of Protection: How Intellectual Property Law Shapes Global Vaccine Inequity and Undermines Pandemic Preparedness

A System Built for Innovation, Not for Equity

The intellectual property regime governing vaccine development in the United States rests on a foundational premise: that patent exclusivity creates the financial incentive necessary to justify the extraordinary costs of pharmaceutical research and development. Under this logic, a manufacturer that invests billions in bringing a novel vaccine to market deserves a period of market monopoly sufficient to recoup that investment and generate profit. The argument is not without merit. The speed at which multiple COVID-19 vaccines reached clinical authorization demonstrated that the innovation pipeline, when properly resourced and incentivized, can perform at a historically unprecedented pace.

But the same period revealed something equally significant and considerably less flattering. As wealthy nations moved with remarkable efficiency to secure vaccine doses for their populations — often purchasing quantities that far exceeded immediate need — lower-income countries waited. They waited not because the vaccines did not exist, nor because the manufacturing capacity to produce them was entirely absent, but because the legal and commercial structures governing vaccine distribution were not designed with equitable global access as a primary objective.

The result was a bifurcated global immunization landscape that public health scholars had warned about for years, made visible in real time by the COVID-19 pandemic and its uneven resolution across the world's populations.

Patent Exclusivity as a Distribution Bottleneck

Under the Agreement on Trade-Related Aspects of Intellectual Property Rights — commonly known as TRIPS — member nations of the World Trade Organization are required to recognize and enforce pharmaceutical patents. For vaccine manufacturers headquartered in the United States or Europe, this framework provides robust protection in the world's wealthiest markets. It also extends the geographic reach of those protections into markets where enforcement may be inconsistent but where the normative pressure to comply remains substantial.

The practical consequence is that manufacturers retain discretionary control over where, to whom, and at what price their vaccines are supplied. During COVID-19, this discretion was exercised in ways that systematically disadvantaged low- and middle-income countries. Advance purchase agreements signed between manufacturers and wealthy governments locked up supply chains before many lower-income nations had secured any commitments at all. Tiered pricing arrangements, where they existed, were often insufficient to overcome procurement barriers rooted in weak health infrastructure and limited foreign exchange.

COVAX, the international vaccine-sharing initiative intended to address this imbalance, was chronically underfunded and operationally dependent on the very surplus donations that wealthy nations chose to release — often after their own populations had received multiple doses. The mechanism, however well-intentioned, functioned as a charitable adjunct to a commercial system rather than a structural corrective to it.

The Compulsory Licensing Gap

TRIPS does contain a provision, affirmed by the 2001 Doha Declaration, permitting member nations to issue compulsory licenses that allow domestic manufacturers to produce patented pharmaceuticals without the patent holder's consent in public health emergencies. In theory, this mechanism offers a pressure valve against the inequities of patent exclusivity. In practice, its utility has been severely constrained.

The pharmaceutical industry and its allied governments — most prominently the United States — have consistently applied diplomatic and commercial pressure against nations that attempt to exercise compulsory licensing rights. South Africa's early efforts to expand access to antiretroviral medications, which were met with a trade dispute initiated by the US government on behalf of pharmaceutical manufacturers, remain a cautionary historical reference point. The implicit message has been durable: countries that challenge patent norms risk economic consequences that may outweigh the public health benefits they seek.

Furthermore, many low-income nations lack the domestic manufacturing infrastructure to make compulsory licensing practically meaningful. A legal right to produce a vaccine is of limited value if the technical capacity, raw material supply chains, and regulatory expertise necessary to exercise that right do not exist. The structural prerequisites for pharmaceutical self-sufficiency are themselves products of decades of underinvestment that patent law does nothing to address.

Pandemic Preparedness as a Collective Action Problem

Perhaps the most consequential dimension of this issue is not the immediate human cost — though that cost, measured in preventable deaths and prolonged disease burden, is substantial — but the systemic risk that vaccine inequity imposes on global health security, including on the United States itself.

Viruses do not observe intellectual property boundaries. Populations that remain unvaccinated, whether because of cost, supply constraints, or distribution failures, constitute reservoirs in which pathogens circulate and, potentially, evolve. The emergence of SARS-CoV-2 variants was shaped in part by the extended periods during which large, unvaccinated populations were exposed to the virus without immunological protection. Each such population represents an opportunity for selective pressure to produce variants that may partially or fully evade vaccine-induced immunity in populations that have been vaccinated.

This dynamic transforms vaccine inequity from a question of distributive justice into a question of epidemiological risk that wealthy nations have a direct self-interest in addressing. Yet American health policy discourse has been slow to internalize this framing. Domestic vaccination debates have largely proceeded as though the relevant population is coterminous with US borders, while the international dimensions of pandemic preparedness have been treated as foreign policy concerns rather than public health imperatives.

Structural Reforms That Remain on the Table

Several policy mechanisms have been proposed to address the structural disconnect between patent-driven vaccine innovation and equitable global distribution. A temporary TRIPS waiver for COVID-19 vaccines was supported by the Biden administration in 2021 — a notable departure from decades of US trade policy — but was ultimately blocked by European Union opposition and never fully implemented in the form its proponents had envisioned.

More durable proposals include the expansion of voluntary licensing pools, greater public investment in open-science vaccine platforms that reduce reliance on proprietary formulations, and sustained funding for regional manufacturing capacity in Africa, Southeast Asia, and Latin America. The mRNA technology underlying several COVID-19 vaccines was developed with substantial public funding, a fact that has renewed scholarly and policy debate about the appropriate balance between public investment and private exclusivity.

Any meaningful reform will require the United States to reckon with its dual role as both a global health leader and a consistent defender of the pharmaceutical industry's intellectual property prerogatives. These roles are not irreconcilable, but navigating the tension between them demands a degree of policy coherence that has not yet been achieved.

Equity and Security as Convergent Imperatives

The immunity paradox — in which the very mechanisms designed to produce vaccines also restrict their reach — is not a flaw incidental to the current system. It is a structural feature of a policy architecture that was built to serve innovation incentives without adequately accounting for distribution outcomes. Resolving it will require more than emergency-era workarounds or incremental charitable contributions.

For the United States, the stakes extend beyond moral obligation. A world in which preventable diseases continue to circulate in unvaccinated populations is a world in which the next pandemic threat is more likely to emerge, more difficult to contain, and more capable of overwhelming even well-resourced health systems. Vaccine equity is not a concession to global altruism. It is a precondition for the domestic health security that American policymakers consistently claim as a priority.